JP2002524421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002524421A5 JP2002524421A5 JP2000568510A JP2000568510A JP2002524421A5 JP 2002524421 A5 JP2002524421 A5 JP 2002524421A5 JP 2000568510 A JP2000568510 A JP 2000568510A JP 2000568510 A JP2000568510 A JP 2000568510A JP 2002524421 A5 JP2002524421 A5 JP 2002524421A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- vegf
- hus
- factor
- organ
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 29
- 238000000034 method Methods 0.000 description 27
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 17
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 17
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 17
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 6
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9969498P | 1998-09-09 | 1998-09-09 | |
| US60/099,694 | 1998-09-09 | ||
| US12640699P | 1999-03-26 | 1999-03-26 | |
| US60/126,406 | 1999-03-26 | ||
| US12661599P | 1999-03-27 | 1999-03-27 | |
| US60/126,615 | 1999-03-27 | ||
| PCT/US1999/020480 WO2000013702A2 (en) | 1998-09-09 | 1999-09-09 | Use of an angiogenic factor for the treatment of microvascular angiopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002524421A JP2002524421A (ja) | 2002-08-06 |
| JP2002524421A5 true JP2002524421A5 (https=) | 2006-10-26 |
Family
ID=27378887
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000568511A Pending JP2002532382A (ja) | 1998-09-09 | 1999-09-09 | 高血圧を処置する方法およびそこでの使用のための組成物 |
| JP2000568510A Pending JP2002524421A (ja) | 1998-09-09 | 1999-09-09 | 微小血管障害の処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000568511A Pending JP2002532382A (ja) | 1998-09-09 | 1999-09-09 | 高血圧を処置する方法およびそこでの使用のための組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US6352975B1 (https=) |
| EP (2) | EP1112083B1 (https=) |
| JP (2) | JP2002532382A (https=) |
| AT (2) | ATE260675T1 (https=) |
| AU (2) | AU5910599A (https=) |
| BR (2) | BR9913533A (https=) |
| CA (2) | CA2340320C (https=) |
| DE (2) | DE69912815T2 (https=) |
| DK (2) | DK1109571T3 (https=) |
| ES (2) | ES2216630T3 (https=) |
| IL (2) | IL141686A0 (https=) |
| PT (2) | PT1109571E (https=) |
| WO (2) | WO2000013702A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2216630T3 (es) * | 1998-09-09 | 2004-10-16 | Scios Inc | Metodos de tratar la hipertension dependiente de la sal. |
| US6783954B2 (en) * | 1999-03-05 | 2004-08-31 | Compugen Ltd. | VEGF nucleic acid and amino acid sequences |
| US7078382B1 (en) | 1999-11-02 | 2006-07-18 | Genentech, Inc. | Modulation of eNOS activity and therapeutic uses thereof |
| IL148674A0 (en) * | 1999-11-02 | 2002-09-12 | Genentech Inc | Modulation of enos activity and therapeutic uses thereof |
| US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| US7820178B2 (en) | 2001-08-01 | 2010-10-26 | University of Brisol | VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents |
| WO2003015605A2 (en) * | 2001-08-20 | 2003-02-27 | University Of Virginia Patent Foundation | Use of s-nitrosothiol signaling to treat disordered control of breathing |
| US7981863B2 (en) * | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
| US7795213B2 (en) | 2001-12-13 | 2010-09-14 | Posco | Methods of contacting β amyloid protein with VEGF |
| US20030171556A1 (en) * | 2001-12-13 | 2003-09-11 | Chi-Bom Chae | Beta-amyloid binding factors and inhibitors thereof |
| US7335362B2 (en) | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
| JP2006068401A (ja) * | 2004-09-03 | 2006-03-16 | Kyushu Institute Of Technology | 人工血管 |
| US7893244B2 (en) * | 2005-04-12 | 2011-02-22 | Intradigm Corporation | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
| JP2008537752A (ja) * | 2005-04-12 | 2008-09-25 | イントラディグム コーポレイション | がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法 |
| EP1964568B1 (en) * | 2005-08-31 | 2014-03-26 | National University Corporation Kagawa University | Utilization of hypertension/hypercardia-preventing effect of d-allose |
| ES2600781T3 (es) | 2008-12-04 | 2017-02-10 | Curna, Inc. | Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf |
| GB0921525D0 (en) * | 2009-12-08 | 2010-01-27 | Isis Innovation | Product and method |
| AU2018244776B2 (en) | 2017-03-30 | 2023-12-14 | Wake Forest University Health Sciences | Methods of treatment for kidney disease |
| CN113418940B (zh) * | 2021-06-24 | 2023-03-14 | 电子科技大学 | 一种基于x射线示踪颗粒的检测方法及检测装置 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456550A (en) | 1982-11-22 | 1984-06-26 | President And Fellows Of Harvard College | Vascular permeability factor |
| US5240848A (en) | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
| WO1990011084A1 (en) | 1989-03-24 | 1990-10-04 | The Regents Of The University Of California | Endothelial cell growth factor, isolation and expression |
| US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
| US5219739A (en) | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
| US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5240714A (en) * | 1989-08-29 | 1993-08-31 | Rof Jose M S | Non-digoxin-like Na+, K+ -ATPase inhibitory factor |
| US5318957A (en) * | 1992-09-02 | 1994-06-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating angiogenesis |
| EP0941116B1 (en) * | 1996-11-01 | 2005-01-19 | Ark Therapeutics Limited | Use of vegf for the manufacture of a medicament for the treatment or prevention of intimal hyperplasia and delivery device |
| US6485942B1 (en) * | 1997-02-14 | 2002-11-26 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production |
| ES2216630T3 (es) * | 1998-09-09 | 2004-10-16 | Scios Inc | Metodos de tratar la hipertension dependiente de la sal. |
-
1999
- 1999-09-09 ES ES99968631T patent/ES2216630T3/es not_active Expired - Lifetime
- 1999-09-09 JP JP2000568511A patent/JP2002532382A/ja active Pending
- 1999-09-09 AT AT99968631T patent/ATE260675T1/de not_active IP Right Cessation
- 1999-09-09 JP JP2000568510A patent/JP2002524421A/ja active Pending
- 1999-09-09 IL IL14168699A patent/IL141686A0/xx unknown
- 1999-09-09 DK DK99968631T patent/DK1109571T3/da active
- 1999-09-09 CA CA002340320A patent/CA2340320C/en not_active Expired - Fee Related
- 1999-09-09 ES ES99946776T patent/ES2211165T3/es not_active Expired - Lifetime
- 1999-09-09 DE DE69912815T patent/DE69912815T2/de not_active Expired - Fee Related
- 1999-09-09 DE DE69915310T patent/DE69915310T2/de not_active Expired - Fee Related
- 1999-09-09 AU AU59105/99A patent/AU5910599A/en not_active Abandoned
- 1999-09-09 EP EP99946776A patent/EP1112083B1/en not_active Expired - Lifetime
- 1999-09-09 PT PT99968631T patent/PT1109571E/pt unknown
- 1999-09-09 CA CA002340728A patent/CA2340728C/en not_active Expired - Fee Related
- 1999-09-09 EP EP99968631A patent/EP1109571B1/en not_active Expired - Lifetime
- 1999-09-09 AT AT99946776T patent/ATE253934T1/de not_active IP Right Cessation
- 1999-09-09 BR BR9913533-7A patent/BR9913533A/pt not_active Application Discontinuation
- 1999-09-09 US US09/392,932 patent/US6352975B1/en not_active Expired - Lifetime
- 1999-09-09 BR BR9913564-7A patent/BR9913564A/pt not_active Application Discontinuation
- 1999-09-09 DK DK99946776T patent/DK1112083T3/da active
- 1999-09-09 WO PCT/US1999/020480 patent/WO2000013702A2/en not_active Ceased
- 1999-09-09 WO PCT/US1999/020481 patent/WO2000013703A2/en not_active Ceased
- 1999-09-09 PT PT99946776T patent/PT1112083E/pt unknown
- 1999-09-09 AU AU60285/99A patent/AU6028599A/en not_active Abandoned
- 1999-09-09 IL IL14168799A patent/IL141687A0/xx unknown
-
2002
- 2002-02-26 US US10/083,817 patent/US20020193288A1/en not_active Abandoned
-
2003
- 2003-12-31 US US10/749,706 patent/US20040224885A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002524421A5 (https=) | ||
| Shah et al. | Comparative evaluation of platelet-rich fibrin with demineralized freeze-dried bone allograft in periodontal infrabony defects: A randomized controlled clinical study | |
| US10314861B2 (en) | Flowable tissue matrices | |
| Siqueira et al. | Bone formation around titanium implants in the rat tibia: role of insulin | |
| Ruszczak | Effect of collagen matrices on dermal wound healing | |
| US9004918B2 (en) | Compositions, assemblies, and methods applied during or after a dental procedure to ameliorate fluid loss and/or promote healing, using a hydrophilic polymer sponge structure such as chitosan | |
| Omata et al. | Enhanced bone regeneration by gelatin–β‐tricalcium phosphate composites enabling controlled release of bFGF | |
| JP2002531193A (ja) | 生きた組織を再生するための方法および物品 | |
| JP2015534945A (ja) | 幹細胞を動員および局在化するための組成物および方法 | |
| JP2002529508A5 (ja) | 移植における免疫応答抑制のための線維芽細胞または線維芽細胞からの上澄みを含む組成物およびその使用法 | |
| CA2263557C (en) | Implant consisting of a carrier material containing medical substances and method to produce such an implant | |
| JP2010518946A5 (https=) | ||
| EP3302523B1 (fr) | Composition pour le traitement des lesions tissulaires | |
| US20170368231A1 (en) | Bioengineered Regenerative Graft Matrix, and Methods for Making Thereof | |
| DE3240909A1 (de) | Zubereitung zur wundheilung und verfahren zu ihrer herstellung | |
| Nie et al. | Improved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model | |
| Yukna et al. | Evaluation of resultant tissue type following the intraoral transplantatin of various lyophilized soft tissues | |
| JP2008536930A5 (https=) | ||
| JP2002534393A5 (https=) | ||
| US20070020245A1 (en) | Composition for the treatment of arthrosis/arthritis, especially for treating joints | |
| CN100479868C (zh) | 激光微孔猪去细胞真皮基质及其制备方法和应用 | |
| WO2005008932A2 (en) | Microporous latex membranes, related articles and methods | |
| JP6448615B2 (ja) | Ｅｃｍ移植組成物および方法 | |
| CN1524521A (zh) | 注射用曲克芦丁及其制备方法 | |
| Smith et al. | Biomaterials in liver tissue engineering |